menu
    • menu

    Company profile for Adial Pharmaceuticals

    NEW Drugs in Dev: 6
    European CDMO and Gx manufacturer with 75 years of experience in delivering premium APIs to pharmaceutical partners worldwide.

    Virtual Booth

    Contact Supplier

    Minakem delivers API, HPAPI, steroids & CDMO services for generics with FDA/GMP certification, regulatory know-how & proven success.

    Virtual Booth

    Contact Supplier

    USP reference standards; highly characterized specimens of drug substances, impurities, excipients, degradation products & more.

    Virtual Booth

    Contact Supplier

    ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

    Virtual Booth

    Contact Supplier

    Seqens is an integrated global leader in pharmaceutical solutions & specialty ingredients, & custom-made solutions to our customers.

    Virtual Booth

    Contact Supplier

    Guizhou Utide Biotechnology Co., Ltd. - Specialized GMP manufacturing for next-generation GLP-1 peptide APIs.

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Adial Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development of a therapeutic agent for the treatment of alcohol use disorder “AUD” using our lead investigational new drug product, AD04. A Phase 2b University of Virginia investigator sponsored clinical trial of AD04 for the treatment of AUD showed promising results and no overt safety concerns (there were no statistically significant serio...
    Adial Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development of a therapeutic agent for the treatment of alcohol use disorder “AUD” using our lead investigational new drug product, AD04. A Phase 2b University of Virginia investigator sponsored clinical trial of AD04 for the treatment of AUD showed promising results and no overt safety concerns (there were no statistically significant serious adverse events reported). The Company plans to commence a Phase 3 clinical trial using AD04 for the potential treatment of AUD in subjects with certain target genotypes.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Adial PharmaceuticalsUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    1001 Research Park Blvd, Ste 100 Charlottesville, VA 22911
    Telephone
    Telephone
    (434) 422-9800
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.adial.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/adial-pharmaceuticals/
    youtube
    YouTube
    Twitter
    Twitter
    https://x.com/AdialPharma

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Default Event

    PBP World Meeting

    Not Confirmed

    envelop Contact Supplier

    PBP World Meeting

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Adial Pharma Reveals 2025 Financials And Business Update
    Adial Pharma Reveals 2025 Financials And Business Update

    06 Mar 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/03/06/3250999/26135/en/Adial-Pharmaceuticals-Reports-2025-Fiscal-Year-Financial-Results-and-Provides-Business-Update.html

    GLOBENEWSWIRE
    06 Mar 2026
    Share Share
    Adial, Molteni Sign AD04 Collaboration Framework for Europe
    Adial, Molteni Sign AD04 Collaboration Framework for Europe

    03 Mar 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/03/03/3248328/26135/en/Adial-Pharmaceuticals-Signs-an-Exclusive-AD04-Collaboration-Framework-with-Molteni-Farmaceutici-for-Europe-which-Anticipates-Nearly-60-Million-in-Potential-Royalties-and-Milestones.html

    GLOBENEWSWIRE
    03 Mar 2026
    Share Share
    Adial Pharma Restores Nasdaq Listing Compliance
    Adial Pharma Restores Nasdaq Listing Compliance

    24 Feb 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/02/24/3243645/26135/en/Adial-Pharmaceuticals-Regains-Full-Compliance-with-Nasdaq-Listing-Requirement.html

    GLOBENEWSWIRE
    24 Feb 2026
    Share Share
    Adial Pharma Spotlights FDA Policy Shift To Cut Pivotal Trials
    Adial Pharma Spotlights FDA Policy Shift To Cut Pivotal Trials

    23 Feb 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/02/23/3242626/26135/en/Adial-Pharmaceuticals-Highlights-FDA-Policy-Direction-That-May-Reduce-Pivotal-Trial-Burden-from-Two-Studies-to-One.html

    GLOBENEWSWIRE
    23 Feb 2026
    Share Share
    Adial Pharma To Present At Oppenheimer Healthcare Conference
    Adial Pharma To Present At Oppenheimer Healthcare Conference

    17 Feb 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/02/17/3239371/26135/en/Adial-Pharmaceuticals-to-Present-at-the-Oppenheimer-36th-Annual-Healthcare-Life-Sciences-Conference.html

    GLOBENEWSWIRE
    17 Feb 2026
    Share Share
    Adial Support Congress Advancing Clinical Trial Endpoint for AD04
    Adial Support Congress Advancing Clinical Trial Endpoint for AD04

    04 Feb 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/02/04/3232184/26135/en/Adial-Applauds-Congressional-Directive-Advancing-Alternative-Clinical-Trial-Endpoints-for-Substance-Use-Disorders-Strengthening-Regulatory-Path-for-AD04.html

    GLOBENEWSWIRE
    04 Feb 2026
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search